Lennox–Gastaut syndrome

Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 6, 2023
Anaphylaxis, FDA, Emergency, Sale, PDUFA, Food, Seizure, Clobazam, Lennox–Gastaut syndrome, EBITDA, Adrenaline, Net, Attention deficit hyperactivity disorder, Regulation of tobacco by the U.S. Food and Drug Administration, Research, Clutch (eggs), Offering, Pharmacokinetics, Senior, Diazepam, PK, New Drug Application, Allergy, NDA, Therapy, Note, Patient, ADHD, Pharmaceutical industry, Video game, Bookkeeping

“We continue to successfully execute on our 2023 key initiatives as demonstrated by our third quarter 2023 results,” said Daniel Barber, Chief Executive Officer of Aquestive.

Key Points: 
  • “We continue to successfully execute on our 2023 key initiatives as demonstrated by our third quarter 2023 results,” said Daniel Barber, Chief Executive Officer of Aquestive.
  • The Company is on track to commence its initial Phase 3 pivotal PK study for Anaphylm in the fourth quarter 2023.
  • Total reported revenues were $13.0 million in the third quarter 2023, compared to $11.5 million in the third quarter 2022.
  • Aquestive is updating its full-year 2023 financial guidance based on third quarter 2023 results and updated outlook for the remainder of 2023.

Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates

Retrieved on: 
Friday, November 3, 2023
Graviton, MB, KCC2, Element, Research, ROCK2, IND, TMS, Seizure, Neuron, IV, Dravet syndrome, Ligand Pharmaceuticals, SAD, Lennox–Gastaut syndrome, Development, Epilepsy, In vivo magnetic resonance spectroscopy, MRS, Transcranial magnetic stimulation, EEG, Status epilepticus, Hemangioma, Pharmaceutical industry, Takeda, Ligand

The remaining 13% interest in these potential future milestone payments and royalties was acquired by Ligand in October 2023.

Key Points: 
  • The remaining 13% interest in these potential future milestone payments and royalties was acquired by Ligand in October 2023.
  • General and administrative expenses were $6.8 million for the three months ended September 30, 2023, as compared to $7.6 million for the same period in 2022.
  • The decrease reflects the impact of headcount reductions conducted as part of organizational changes made in the first half of 2023.
  • Total operating expenses were $12.1 million for the three months ended September 30, 2023, as compared to $12.8 million for the same period last year.

Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 2, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, Insurance, MSCE, ATM, FINANCIAL, MPH, Medication, Development of the human body, American Epilepsy Society, MD, Children's Hospital of Philadelphia, Dravet syndrome, SAD, Lennox–Gastaut syndrome, Caregiver, Clinical trial, Longboard, DSM-IV codes, NUALS Arts and Literary Annual Meet, Philadelphia, AES, Pacific studies, Investment, Hospital, DEE, Child, Pharmaceutical industry

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2023.
  • “We look forward to PACIFIC Study topline data in January 2024 evaluating LP352 in people living with Developmental and Epileptic Encephalopathies, or DEEs.
  • DEE caregivers and healthcare providers continue to be frustrated with the lack of new treatment options and remain focused on finding treatment options that balance safety, efficacy and burden.
  • We look forward to Phase 1 SAD data in the first half of 2024,” stated Kevin R. Lind, Longboard’s President and Chief Executive Officer.

International Lennox-Gastaut Syndrome (LGS) Awareness Day, November 1st, Will Kick Off Epilepsy Awareness Month

Retrieved on: 
Thursday, October 26, 2023
Social media, International, Hope, Lennox–Gastaut syndrome, Research, Volunteering, Sibling, Learning, Disease, Philadelphia International Airport, Cystic fibrosis, Epilepsy, LGS, Gillette Stadium, Diagnosis, SAN

SAN DIEGO, Oct. 26, 2023 /PRNewswire/ -- On November 1st, the Lennox-Gastaut Syndrome (LGS) Foundation will join families, researchers, clinicians, and advocates around the world to observe International LGS Awareness Day .

Key Points: 
  • SAN DIEGO, Oct. 26, 2023 /PRNewswire/ -- On November 1st, the Lennox-Gastaut Syndrome (LGS) Foundation will join families, researchers, clinicians, and advocates around the world to observe International LGS Awareness Day .
  • On this day, thousands of individuals and families impacted by LGS will come together to increase public awareness of this devastating rare disease.
  • Lennox-Gastaut Syndrome (LGS) is a severe epilepsy syndrome that develops in young children and typically leads to lifelong disability.
  • Each November, the LGS Foundation organizes a global social media campaign and several awareness events to raise awareness and share stories of hope.

Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026

Retrieved on: 
Wednesday, October 18, 2023
Dravet syndrome, Lennox–Gastaut syndrome, Epilepsy, Growth, Seizure, LGS, Finance, SAN, Pharmaceutical industry, Takeda, Ligand

In return, Ovid will receive a $30 million payment, less certain reimbursable expenses.

Key Points: 
  • In return, Ovid will receive a $30 million payment, less certain reimbursable expenses.
  • “We are pleased to partner with Ligand which recognizes the potential value of our royalty and milestone payments associated with soticlestat,” said Jeffrey Rona, Chief Business and Financial Officer of Ovid.
  • With this additional, non-dilutive capital infusion from Ligand, Ovid anticipates that its cash runway is expected to last into 2026 and will enable the expansion of its clinical programs.
  • Ovid has no ongoing obligations or costs associated with the development of soticlestat.

At the Lennox-Gastaut Syndrome Foundation's Meeting of the Minds, Bringing Patient Families and Scientists Together is the Secret Sauce to Advancing Patient Prioritized Research

Retrieved on: 
Wednesday, September 6, 2023
Seizure, Medical school, LGS, University, Education, Sleep, Research, Doctor of Philosophy, Dementia, Behavior, History of the University of Maryland, College Park, School, Lennox–Gastaut syndrome, Caregiver, Epilepsy, Nursing

The goal of this important meeting is for patient families and researchers to work together to identify and prioritize gaps in LGS research.

Key Points: 
  • The goal of this important meeting is for patient families and researchers to work together to identify and prioritize gaps in LGS research.
  • Lennox-Gastaut Syndrome (LGS) is a rare, severe, life-threatening, epilepsy syndrome that develops in children and leads to frequent seizures, cognitive decline, and lifelong disability.
  • Research shows that for the majority with LGS, this strategy fails, and we don't have a natural history study that learns from every patient.
  • We believe that bringing families living with LGS together with scientists is the secret sauce to changing this strategy and advancing research in LGS."

Researchers Use the Simulations Plus DILIsym® Platform to Predict Safety of Combined CBD and VPA Treatment

Retrieved on: 
Tuesday, August 15, 2023
Technology, Health Technology, Software, Biotechnology, Other Health, Health, Pharmaceutical, Data Management, Artificial Intelligence, Seizure, Drug development, SLP, Clinical Pharmacology & Therapeutics, Lennox–Gastaut syndrome, Simulations Plus, QST, Chapel Hill, Liver injury, Dravet syndrome, Risk, Hepatotoxicity, Drug design, Incidence, Patient, Manuscript, University, History of the University of North Carolina at Chapel Hill, ALT, FDA, Therapy, VPA, Cannabidiol, Safety, Medical device, Dietary supplement, Pharmaceutical industry, CBD

CBD is an FDA-approved treatment for seizures in patients diagnosed with Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex.

Key Points: 
  • CBD is an FDA-approved treatment for seizures in patients diagnosed with Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex.
  • During the pre-approval clinical trials, treatment with CBD was occasionally associated with elevation in blood levels of ALT, a marker of liver injury, but this was much more common in patients already receiving treatment with VPA for seizures.
  • To identify potential underlying mechanisms, researchers used DILIsym to predict ALT levels in simulated populations that were treated with CBD alone, treated with VPA alone, and then treated with VPA before they were treated with CBD.
  • DILIsym predicted dose-dependent ALT elevations for CBD treatment and ALT elevations for VPA treatment when each was given alone, but the combined VPA and CBD treatment protocol mimicking the clinical trials did not increase the incidence of ALT elevations relative to CBD treatment on its own.

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 10, 2023
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, RSE, Biomedical Advanced Research and Development Authority, Therapy, SG, U.S. Department of Defense Strategy for Operating in Cyberspace, European Commission Investment Plan for Europe, Human services, Office of Inspector General, U.S. Department of Health and Human Services, Lennox–Gastaut syndrome, API, CDKL5 deficiency disorder, Clinical trial, G&A, GAAP, Medication, TSC, Development, Administration, RAISE, European Commission, Patent, Patient, Investment, Administration for Strategic Preparedness and Response, Epilepsy, Ganaxolone, MAD, Growth, Security (finance), R, Research, BARDA, IND, Marigold, Pharmaceutical industry, Cryptocurrency, Fine chemical

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the second quarter ended June 30, 2023.

Key Points: 
  • Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the second quarter ended June 30, 2023.
  • Recognized $4.2 million and $7.6 million in net product revenues for the three and six months ended June 30, 2023, respectively.
  • Net product revenue consists of ZTALMY product sales, which was launched in the U.S. in the third quarter of 2022.
  • At June 30, 2023, the Company had cash, cash equivalents, and short-term investments of $175.3 million, compared to $240.6 million at December 31, 2022.

NeuroPace Reports Second Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance

Retrieved on: 
Tuesday, August 8, 2023
Epilepsy, Insurance, LGS, Partnership, SG, Telephone, Lennox–Gastaut syndrome, Clinical trial, Neurosurgery, Hemispherectomy, Level 4, Trial of the century, Responsive neurostimulation device, Patient, Physician, Investment, EEG, Webcast, Growth, FDA, Conference, NIH, RNS, Total, Pharmaceutical industry, Clothing, Rare-earth element, Video game, Nursing

MOUNTAIN VIEW, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • Achieved total revenue of $16.5 million for the second quarter of 2023, representing a 62% increase over the second quarter of 2022.
  • Gross margin for the second quarter of 2023 was 72.5% compared to 73.2% in the second quarter of 2022 and 71.7% in the first quarter of 2023.
  • Net loss was $9.1 million for the second quarter of 2023, compared to a net loss of $12.7 million in the second quarter of 2022.
  • NeuroPace will host a conference call to discuss the second quarter 2023 financial results after market close on Tuesday, August 8, 2023, at 4:30 P.M. Eastern Time.

Aquestive Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, August 7, 2023
Epilepsy, Seizure, Tmax, Clobazam, Food, Allergy, Emergency, ADHD, NDA, Attention deficit hyperactivity disorder, Research, Cmax, Patient, Anaphylaxis, Adrenaline, Lennox–Gastaut syndrome, FDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Diazepam, Pharmaceutical industry, Dietary supplement, Video game, Bookkeeping

“Our strong second quarter 2023 results continue to drive the Company forward,” said Daniel Barber, Chief Executive Officer of Aquestive.

Key Points: 
  • “Our strong second quarter 2023 results continue to drive the Company forward,” said Daniel Barber, Chief Executive Officer of Aquestive.
  • The Company manufactured approximately 48 million doses in the second quarter 2023, compared to 47 million in the second quarter 2022.
  • Total reported revenues were $13.2 million in the second quarter 2023, compared to $13.3 million in the second quarter 2022.
  • Aquestive is updating its full-year 2023 financial guidance based on second quarter 2023 results and updated outlook for the remainder of 2023.